)

Marinus Pharmaceuticals (MRNS) investor relations material
Marinus Pharmaceuticals Investor Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Product and clinical overview
Ganaxolone is a neuroactive steroid that modulates both synaptic and extrasynaptic GABA receptors, offering a differentiated mechanism of action for epilepsy treatment.
ZTALMY (ganaxolone) is FDA-approved for CDKL5 deficiency disorder (CDD) and has a well-characterized safety profile, addressing a significant unmet need.
In the Phase 3 Marigold trial, ganaxolone reduced major motor seizure frequency by a median of 30.7% versus 6.9% for placebo; sustained reductions of ~50% were observed over two years in the open-label extension.
The most frequent adverse events were somnolence, pyrexia, and upper respiratory tract infection, with safety findings consistent across studies.
Commercial performance and strategy
Net product revenue for ZTALMY reached $8.5M in Q3 2024, a 56% increase from Q3 2023, with full-year revenue expected at $33–34M.
Achieved profitability on ZTALMY commercial investment in Q1 2024, ahead of target, driven by strong patient enrollments and prescriber growth.
Commercial strategy includes focused education for healthcare providers, enhanced patient support, and increased investment in patient identification.
Global access is expanding through partnerships in Europe (Orion), China (Tenacia), MENA (Biologix), and a distribution agreement with Uniphar Group.
Clinical pipeline and trial results
In the Phase 3 TrustTSC trial for TSC-associated seizures, ganaxolone showed a 19.7% reduction in seizure frequency versus 10.2% for placebo; the primary endpoint was not statistically significant (p=0.0904).
The RAISE Phase 3 trial in refractory status epilepticus (SE) showed IV ganaxolone led to SE cessation within 30 minutes in 80% of patients versus 13% for placebo (p<0.0001), with similar rates of serious adverse events.
Median time to SE cessation was 4.2 minutes for IV ganaxolone versus 307.2 minutes for placebo; EEG seizure burden reduction was 93% for ganaxolone versus 36% for placebo (p=0.003).
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage